With nod from panel, Aerie inches toward FDA approval

Aerie Pharmaceuticals (Nasdaq: AERI) – which is in the process of building out its research and development team locally – is moving closer to U.S. Food and Drug Administration approval. On Friday, an FDA advisory committee voted in favor of Rhopressa – an Aerie eye drop product candidate for the treatment of glaucoma. The 10-pe rson panel voted unanimously that clinical trials of Rhopressa support its efficacy; it voted 9-1 that its efficacy outweighs safety risks. While the FDA normally…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news